Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced the launch of FilterTool, an advanced web-based
application for genetic data interpretation.
The new FilterTool application seamlessly integrates with
CENTOGENE’s CE-marked Software as a Service (SaaS) bioinformatics
pipeline, CentoCloud®, as an accessory and enables laboratories,
medical experts, and bioinformaticians to efficiently display,
filter, select, and classify relevant genetic variants identified
by Next Generation Sequencing (NGS) data analysis. This will allow
CentoCloud® users to visualize key genetic variants of concern for
any given patient.
This state-of-the-art FilterTool functionality will empower
users around the world to make clinical decisions for their
patients, fueled by the knowledge of approximately 700,000
individuals from over 120 highly diverse countries in the CENTOGENE
Biodatabank. The FilterTool is powered by this vast multiomic
dataset containing unique variants and insights from over 2,500
rare and neurodegenerative diseases and integrates less specialized
common public databases. In turn, this will support accelerated
diagnostic turnaround times for patients and bring greater insights
into the genetic factors of diseases for physicians and
researchers.
The strength of pairing the FilterTool with CentoCloud® is
underlined by the uniquely integrated feature that allows users to
select the top 25 disease-causing variants out of the tens of
thousands of variants found in a typical exome analysis.
These advanced filters are based on extensively curated
annotations from CENTOGENE’s team of medical and bioinformatics
experts, proprietary prioritization ranks and scores, and the
American College of Medical Genetics and Genomics (ACMG)
guideline-based pre-classification.
“At CENTOGENE, we deliver data-driven, life-changing answers to
accelerate precision medicine, and this latest application release
is the embodiment of our mission,” said Prof. Peter Bauer,
CENTOGENE’s Chief Medical and Genomic Officer. “The new FilterTool
application is an innovation that was designed by physicians, for
physicians, and when combined with CentoCloud®, significantly
accelerates genetic variant interpretation. Ultimately, this paves
the way to enhanced diagnostics and supports breakthrough
discoveries.”
CENTOGENE’s FilterTool is one of the world’s only CE-marked In
Vitro Diagnostic Regulation (IVDR 2017/746) filtering applications
to support experts in genomic diagnostics, following new regulatory
framework from the European Parliament last year.
To schedule a demo and learn more about how CentoCloud® and the
FilterTool application facilitate the same high quality and
diagnostic accuracy as CENTOGENE offers in its own certified
state-of-the-art labs, visit:
https://link.centogene.com/3QUJLSk
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with nearly
700,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 260 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target & drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a
world healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward- looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth, execute our business strategy and enter
into new client relationships, our dependency on the rare disease
industry, our ability to manage international expansion, our
reliance on key personnel, our reliance on intellectual property
protection, fluctuations of our operating results due to the effect
of exchange rates, our ability to streamline cash usage, our
continued ongoing compliance with covenants linked to financial
instruments, our requirement for additional financing, or other
factors. For further information on the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to
CENTOGENE’s business in general, see CENTOGENE’s risk factors set
forth in CENTOGENE’s Form 20-F filed on March 31, 2022, with the
Securities and Exchange Commission (the “SEC”) and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and
CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Contact:
CENTOGENE
Ben Legg Corporate
Communications Press@centogene.com
Lennart StreibelInvestor RelationsIR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jul 2023 to Jul 2024